Hikma Pharmaceuticals (H5P) AI Stock Analysis

4 Followers

Hikma Pharmaceuticals

(Frankfurt:H5P)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Diversified Pharmaceutical PortfolioA broad product mix across generic, branded-generic and injectable medicines gives Hikma multiple revenue streams and reduces reliance on one therapeutic area or geography. Its established presence across regions and healthcare channels supports durable market access and business resilience.

Negative Factors

Sharp Cash Flow Step-DownThe substantial decline in operating and free cash flow reduces internally generated funding for investment, debt reduction and shareholder returns. Free cash flow also lagged net income materially, making cash conversion a key execution concern if the weaker pattern persists.

Hikma Pharmaceuticals (H5P) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 3.40B
Dividend Yield: 3.73%
Average Volume (3M): 825
Price to Earnings (P/E): 12.2
Beta (1Y): 0.53
Revenue Growth: -0.88%
EPS Growth: 0.05%
Country: Germany
Employees: 9,500
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Hikma Pharmaceuticals Business Overview & Revenue Model

Company Description

Hikma Pharmaceuticals PLC is a global pharmaceutical enterprise involved in the creation, production, promotion, and distribution of a wide array of generic, branded, and licensed medicinal solutions. These offerings are presented in various dosage f...

Hikma Pharmaceuticals Earnings Call Summary

Earnings Call Date:Aug 06, 2026(Q2-2026)|% Change Since:8.65%|Next Earnings Date:Feb 25, 2027

Earnings Call SentimentNeutral

The call conveyed balanced progress: strong H1 operational and financial performance (EBIT/EBITDA up ~8%, EPS up ~5%), clear operational fixes in injectables, solid MENA momentum, advancing product launches (TYZAVAN, tapentadol) and CMO pipeline, and near‑term proof of capital return via buybacks. Offsetting this are meaningful H2 risks (historical H1 tender weighting and stockpiling normalisation), ongoing price erosion in parts of Rx, divestment of a loss‑making 503B unit, and elevated H2 investment that will temper near‑term margins. Management reiterated full‑year guidance and emphasised continued investment for medium‑term growth (CMO, R&D, US capacity). Overall the positives are meaningful but matched by tangible short‑term headwinds and execution/market risks.

Positive Updates

Profitability Improvement (EBIT / EBITDA)

EBIT and EBITDA increased by almost 8% in H1 2026, reflecting stronger operating performance and margin management.

Negative Updates

Second‑Half Branded Weighting and Caution

Branded / MENA and tender activity is historically H1‑weighted (management noted H1 ~55% of sales) and management signalled a material second‑half slowdown in branded revenues and operating profit relative to H1, prompting caution and maintenance of conservative full‑year guidance despite strong H1 results.

Company Guidance

Hikma reiterated its FY2026 guidance of group revenue growth of 2–4% and operating profit of $720–$770m (H1 operating profit was $405m), after H1 delivered EBIT and EBITDA up almost 8% and EPS up ~5%; management said branded/tender sales are H1‑weighted (around 55% of sales in H1), R&D and promotion spend will increase in H2, and inflation has been absorbed so far. Other metrics called out: buyback ~complete (~$230m spent to buy ~11–12m shares, ~$20m remaining), ~80% of Vanco Ready customers have switched to TYZAVAN, injectable and CMO revenues are expected to pick up in H2 (Rx CMO still tracking to a 20% of Rx‑revenue target by 2030), the 503B compounding unit is classified as held for sale (expected within 12 months), and major capacity additions (Bedford plant due in 2028) underpin the outlook.

Hikma Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:H5P against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:HLN	63Neutral	GBP 29.41B	18.70	9.89%	1.36%	1.21%	8.33%
GB:VLG	62Neutral	GBP 82.02M	16.05	7.82%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:STX	43Neutral	GBP 35.45M	-4.47	64.57%	―	36.19%	60.75%
GB:AGY	42Neutral	GBP 88.66M	-1.46	409.00%	―	2.94%	-32.00%

* Healthcare Sector Average

Performance Comparison

DE:H5P and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:H5P	Hikma Pharmaceuticals	19.74	2.54	14.77%
GB:AGY	Allergy Therapeutics	1.45	-7.05	-82.94%
GB:STX	Shield Therapeutics	3.30	-3.40	-50.75%
GB:VLG	Venture Life	70.00	11.00	18.64%
GB:BXP	Beximco Pharmaceuticals Limited Sponsored GDR RegS	62.50	23.80	61.52%
GB:HLN	Haleon PLC	339.20	-29.82	-8.08%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Hikma Pharmaceuticals AI Stock Analysis